Laura Turco
@Laura_Turco83
Followers
485
Following
825
Media
28
Statuses
323
MD, PhD. Transplant Hepatologist
Bologna, Emilia Romagna
Joined April 2018
A sad loss 😔.
EASL joins the global hepatology community in mourning the passing of Prof. Jaime Bosch, a visionary clinician-scientist, educator, and leader whose legacy has shaped our field over the past five decades. From pioneering research in portal hypertension to mentoring generations
0
1
7
NSSB do lower the risk of first decompensation even in patients with cirrhosis and treated etology!. Thank you @JosephHabibi_MD for highlighting our study! .@AGA_CGH .@md_linaa .@BavenoCoop.
#CGH4ALL 📣.🩺 NSBBs reduce first decompensation risk in cirrhosis w/ enduring CSPH.💥 Significant impact even in small GEVs and hepatitis C-cured patients!.👇 Read the full study from @AGA_CGH. 🔗 Reported by @arianapg. @Laura_Turco83 @AlessioGerussi
1
9
18
Generate videos in just a few seconds. Try Grok Imagine, free for a limited time.
836
3K
10K
RT @JHEP_Reports: ❗Liver transplantation for HBV-related liver disease: Impact of prophylaxis for #HBV on #HCC recurrence. 🔓#OpenAccess at….
0
3
0
RT @EASLnews: The authors of today’s #readoftheweek📚 discuss the results from the first nationwide study on liver transplant for patients w….
0
4
0
❤️ Teamwork makes the dream work! ❤️.
#LiverX @BavenoCoop #TopCitedArticle. Happy to share that our review authored by .Drs. @LauraTurco @GiovanniVitali @VincenzoLaMura is a top cited article in @LiverInt . 🔗
1
1
12
RT @BavenoCoop: 🚨 Today is the day 🚨. The #Baveno8 Pre-Symposium Webinar is happening today 🎉. 🔬 Cutting-edge topics on ACLD, Win Ratio, Ba….
0
5
0
RT @BavenoCoop: 🚨 2 days to go‼️. ✅ RCT challenges in ACLD.✅ Win ratio & ordinal outcomes.✅ Heterogeneity of Tx. effects.✅ Surrogate outcom….
0
7
0
RT @BavenoCoop: And last but not least. 💡Uncover the methodological pitfalls in observational studies in Hepatology. Ensure your researc….
0
7
0
RT @BavenoCoop: ❓How can Bayesian inference enhance RCTs and observational studies?. 💡Discover how to leverage this powerful approach to im….
0
9
0
RT @BavenoCoop: ❓How can we go beyond binary outcomes in assessing treatment effects in ACLD? . 💡Learn about hierarchical outcomes, recurre….
0
9
0
RT @BavenoCoop: 🎄 Wishing everyone a Merry Christmas and Happy Holidays from all of us at @BavenoCoop ‼️. ✨ Here's to a joyful season and a….
0
5
0
RT @JIFortea: 🚨 It is finally here‼️. 📜 Carvedilol vs. Propranolol for preventing decompensation and mortality in compensated & decompensat….
0
133
0
RT @BavenoCoop: 🚨Be aware @BavenoCoop members!! . 🗓️TODAY is the virtual General Assembly at 17:00 PM (CEST). ⛓️💥Zoom link sent to all mem….
0
4
0
RT @BavenoCoop: 🚨Don’t miss the Baveno VIII Pre-Symposium Webinar: Designing Clinical Studies in Advanced Chronic Liver Disease . A must-a….
0
24
0
RT @AisfFegato: Si è aperto oggi a Roma il 4° "AISF Training Day" della Scuola di Epatologia AISF, dal titolo "Bedside Approach and Precisi….
0
3
0
RT @JHEP_Reports: 🟪NEW Article in press❕. Liver transplantation for HBV-related liver disease: impact of prophylaxis for HBV on HCC recurre….
0
13
0
RT @BavenoCoop: Join the @BavenoCoop family to:. 1️⃣ Stay updated on #PortalHypertension.2️⃣ Participate in studies.3️⃣ Young/experienced m….
0
8
0
What a news from @LiverInt! 🥳.Our review on CARVEDILOL IN PORTAL HYPERTENSION has received over 20,000 views since publication! 🥰.@ReibergerThomas @VincenzoLaMura @GiovanniVitale.🔽 #ViewsMilestone.
onlinelibrary.wiley.com
Portal hypertension (PH) is the most common complication ofcirrhosis and represents the main driver of hepatic decompensation. The overarching goal of PH treatments in patients with compensated...
0
6
47
Check-out our last article!. 🔽.β-blockers lower first decompensation in patients with cirrhosis and enduring portal hypertension after etiological treatment. @MadalinaTaru .@horstef.@bogdanprocopet.@BavenoCoop.
cghjournal.org
Non-selective beta-blockers (NSBBs) can lower the risk of first decompensation in patients with cirrhosis and clinically significant portal hypertension (CSPH) (identified by a hepatic venous...
2
20
55